Tur MK - Search Results

1

Recombinant CD64-specific single chain immunotoxin exhibits specific cytotoxicity against acute myeloid leukemia cells.

Tur MK, Huhn M, Thepen T, Stöcker M, Krohn R, Vogel S, Jost E, Osieka R, van de Winkel JG, Fischer R, Finnern R, Barth S. Tur MK, et al. Cancer Res. 2003 Dec 1;63(23):8414-9. Cancer Res. 2003. PMID: 14679004

2

In vivo efficacy of the recombinant anti-CD64 immunotoxin H22(scFv)-ETA' in a human acute myeloid leukemia xenograft tumor model.

Tur MK, Huhn M, Jost E, Thepen T, Brümmendorf TH, Barth S. Tur MK, et al. Int J Cancer. 2011 Sep 1;129(5):1277-82. doi: 10.1002/ijc.25766. Epub 2011 Feb 26. Int J Cancer. 2011. PMID: 21077160

3

An anti-GD2 single chain Fv selected by phage display and fused to Pseudomonas exotoxin A develops specific cytotoxic activity against neuroblastoma derived cell lines.

Tur MK, Sasse S, Stöcker M, Djabelkhir K, Huhn M, Matthey B, Gottstein C, Pfitzner T, Engert A, Barth S. Tur MK, et al. Int J Mol Med. 2001 Nov;8(5):579-84. doi: 10.3892/ijmm.8.5.579. Int J Mol Med. 2001. PMID: 11605031

4

Human angiogenin fused to human CD30 ligand (Ang-CD30L) exhibits specific cytotoxicity against CD30-positive lymphoma.

Huhn M, Sasse S, Tur MK, Matthey B, Schinköthe T, Rybak SM, Barth S, Engert A. Huhn M, et al. Among authors: tur mk. Cancer Res. 2001 Dec 15;61(24):8737-42. Cancer Res. 2001. PMID: 11751393

5

Fcgamma receptor 1 (CD64), a target beyond cancer.

Thepen T, Huhn M, Melmer G, Tur MK, Barth S. Thepen T, et al. Among authors: tur mk. Curr Pharm Des. 2009;15(23):2712-8. doi: 10.2174/138161209788923967. Curr Pharm Des. 2009. PMID: 19689341 Review.

6

Recombinant, ETA'-based CD64 immunotoxins: improved efficacy by increased valency, both in vitro and in vivo in a chronic cutaneous inflammation model in human CD64 transgenic mice.

Ribbert T, Thepen T, Tur MK, Fischer R, Huhn M, Barth S. Ribbert T, et al. Among authors: tur mk. Br J Dermatol. 2010 Aug;163(2):279-86. doi: 10.1111/j.1365-2133.2010.09824.x. Epub 2010 Apr 26. Br J Dermatol. 2010. PMID: 20426788

7

Recombinant soluble human Fcgamma receptor I with picomolar affinity for immunoglobulin G.

Paetz A, Sack M, Thepen T, Tur MK, Bruell D, Finnern R, Fischer R, Barth S. Paetz A, et al. Among authors: tur mk. Biochem Biophys Res Commun. 2005 Dec 30;338(4):1811-7. doi: 10.1016/j.bbrc.2005.10.162. Epub 2005 Nov 2. Biochem Biophys Res Commun. 2005. PMID: 16289041

8

Granzyme B-H22(scFv), a human immunotoxin targeting CD64 in acute myeloid leukemia of monocytic subtypes.

Stahnke B, Thepen T, Stöcker M, Rosinke R, Jost E, Fischer R, Tur MK, Barth S. Stahnke B, et al. Among authors: tur mk. Mol Cancer Ther. 2008 Sep;7(9):2924-32. doi: 10.1158/1535-7163.MCT-08-0554. Mol Cancer Ther. 2008. PMID: 18790773 Free article.

9

In vitro effects and ex vivo binding of an EGFR-specific immunotoxin on rhabdomyosarcoma cells.

Niesen J, Brehm H, Stein C, Berges N, Pardo A, Fischer R, Ten Haaf A, Gattenlöhner S, Tur MK, Barth S. Niesen J, et al. Among authors: tur mk. J Cancer Res Clin Oncol. 2015 Jun;141(6):1049-61. doi: 10.1007/s00432-014-1884-z. Epub 2014 Nov 30. J Cancer Res Clin Oncol. 2015. PMID: 25433506

10

Novel PSCA targeting scFv-fusion proteins for diagnosis and immunotherapy of prostate cancer.

Kessler C, Pardo A, Tur MK, Gattenlöhner S, Fischer R, Kolberg K, Barth S. Kessler C, et al. Among authors: tur mk. J Cancer Res Clin Oncol. 2017 Oct;143(10):2025-2038. doi: 10.1007/s00432-017-2472-9. Epub 2017 Jun 30. J Cancer Res Clin Oncol. 2017. PMID: 28667390

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

42 results

Search Page

Filters